News|Articles|October 6, 2026

10 Nephrology Headlines You Missed in Q3 2026

Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.

Nephrology news in the third quarter of 2026 included 5 US Food and Drug Administration (FDA) approvals across IgA nephropathy (IgAN), chronic kidney disease (CKD), and nephrotic syndrome, along with 2-year trial data for therapies first approved on the basis of proteinuria.

Related to this article

October 5th, 2026

Nephrology in September 2026: FDA approves finerenone for CKD in T1D and obinutuzumab for nephrotic syndrome, plus ORIGIN 3 IgAN data.

October 1st, 2026

FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.

October 6th, 2026

Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.

October 6th, 2026

Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.

October 6th, 2026

Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.

October 6th, 2026

Hematology in September 2026: ASH raises ferritin thresholds for iron deficiency, plus marstacimab in hemophilia and curative SCD care.

October 6th, 2026

Strong recommendations cover carvedilol or banding for varices, semiannual HCC surveillance, vaccines, and smoking cessation.

October 6th, 2026

April Armstrong, MD, MPH, discusses 1-year RELIEVE-AD-PEDs data on rapid, sustained dupilumab disease control in adolescents with atopic dermatitis.